See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
The Oscars
Volodymyr Zelenskyy
Ukraine War
Academy Awards
Social Media
Artificial Intelligence
Baseball
Donald Trump
Basketball
Tariffs
Athletics
European Union
Published • loading... • Updated

AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race - GUBRA A S by GUBRA A S (OTC:GUBRF), AbbVie (NYSE:ABBV)

  • AbbVie has entered the obesity treatment market by licensing Gubra's drug GUB014295, which aims to compete with existing therapies from Novo Nordisk and Eli Lilly.
  • AbbVie will manage the development and commercialization of GUB014295, which has completed a Phase 1 trial with promising results.
  • The drug GUB014295 is an amylin analog currently in Phase 1 trials, aimed at regulating appetite and blood sugar levels.
Insights by Ground AI
Does this summary seem wrong?

11 Articles

All
Left
Center
3
Right
1
BenzingaBenzinga

AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race - GUBRA A S by GUBRA A S (OTC:GUBRF), AbbVie (NYSE:ABBV)

On Monday, AbbVie Inc (NYSE:ABBV) and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial. “Our partnership with Gubra marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company,” said Robert Michael, CEO of AbbVie. Also Read: Is …

·New York, United States
Read Full Article
biopharmadive.combiopharmadive.com

AbbVie gets into obesity with $350M deal for once-weekly shot

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.

Read Full Article
STATSTAT

AbbVie steps into the obesity drug race, licensing medicine from Danish firm

The deal includes a $350 million upfront payment and potentially $1.9 billion depending on certain milestones being met.

·Boston, United States
Read Full Article
Business DailyBusiness Daily

AbbVie partners with Gubra for obesity treatment using amylin analog

AbbVie and Gubra have announced a license agreement to develop an amylin analog, GUB014295, for obesity treatment. This collaboration marks AbbVie's entry into the obesity field and involves incorporating Gubra's peptide into AbbVie's global development and commercialization infrastructure."At AbbVie, we are focused on transforming the future of patient care in areas where significant unmet need persists," said Robert A. Michael, CEO of AbbVie. …

·Arizona, United States
Read Full Article
MedCity NewsMedCity News

AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic

AbbVie is licensing rights to a drug from Gubra that has encouraging early clinical data in obesity. The once-weekly injectable peptide is a dual agonist of the amylin and calcitonin receptors, both of which play key roles in metabolism. The post AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic appeared first on MedCity News.

Read Full Article
pipelinereviewpipelinereview

AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity - Pipelinereview

Partnership marks AbbVie’s entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie’s global infrastructure for developing and commercializing therapies for patients in need NORTH CHICAGO, IL, USA and HØRSHOLM, Denmark I March 3, 2025 I AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and p…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 75% of the sources are Center
75% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Business Daily broke the news in Arizona, United States on Monday, March 3, 2025.
Sources are mostly out of (0)

Similar News Topics

Pharma

Pharma

Obesity

Obesity

Eli Lilly

Eli Lilly

Infrastructure

Infrastructure

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal